WO2004073622A2 - Novel therapeutic method and compositions for topical administration - Google Patents
Novel therapeutic method and compositions for topical administration Download PDFInfo
- Publication number
- WO2004073622A2 WO2004073622A2 PCT/US2004/004329 US2004004329W WO2004073622A2 WO 2004073622 A2 WO2004073622 A2 WO 2004073622A2 US 2004004329 W US2004004329 W US 2004004329W WO 2004073622 A2 WO2004073622 A2 WO 2004073622A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- nominal flux
- photoageing
- drug substance
- case
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- This invention relates to a novel therapeutic method, in particular to a method of treatment of diseases associated with the skin and to pharmaceutical compositions and their use in such method.
- a class of compounds known as thiazolidinediones known as thiazolidinediones
- NIDDM non insulin dependent diabetes mellitus
- the thiazolidinedione troglitazone was shown to have these same beneficial effects in human patients suffering from impaired glucose tolerance, a metabolic condition that precedes the development of NIDDM, as in patients suffering from NIDDM (J. J. Nolan et. al., N. Eng. J. Med. 1188-1193, 331 (1994)).
- thiazolidinediones do not cause increases in insulin secretion or in the number or affinity of insulin receptor binding sites, suggesting that thiazolidinediones amplify post-receptor events in the insulin signaling cascade (J. R. Colca and D. R. Morton, "Antihyperglycemic thiazolidinediones: ciglitazone and its , analogs," in New Antidiabetic Drugs, C. J. Bailey and P. R. Flatt, eds., Smith-Gordon, New York, 255-261 (1990)). Thiazolidinediones also induce the in vitro differentiation of preadipocyte cell lines into mature adipocytes (A.
- PPAR-gamma Peroxisome Proliferator- Activated Receptor gamma
- PPAR-alpha Three mammalian PPARs have been isolated and termed PPAR-alpha, PPAR-gamma, and NUC-1 , or PPAR ⁇ . These PPARs regulate expression of target genes by binding to DNA sequence elements, termed PPAR response elements (PPRE).
- PPRE PPAR response elements
- PPRE's have been identified in the enhancers of a number of genes encoding proteins that regulate lipid metabolism suggesting that PPARs play a pivotal role in the adipogenic signaling cascade and lipid homeostasis (H. Keller and W. Wahli, Trends Endocrin. Met. 291- 296, 4 (1993)).
- Thiazolidinediones are now known to be potent and selective activators of PPAR-gamma and bind directly to the PPAR-gamma receptor (J..M. Lehmann et. al., J. Blol. Chem. 12953-12956, 270 (1995)), providing evidence that PPAR-gamma is a possible target for the therapeutic actions of the thiazolidinediones.
- PPAR-gamma was identified as a key molecular target for thiazolidinediones, this nuclear transcription factor has been identified in a large number of human cell types, and thiazolidinediones have been claimed to have a broad spectrum of potential clinical utilities, for example in certain forms of cancer (e.g. G.D. Demetri et al., Proc. Natl. Acad. Sci. USA 3951-3956, 96 (1999)), multiple sclerosis (e.g. M. Niino et al., Neuroimmunology 40-48, 116 (2001)), Alzheimer's Disease (e.g. G. S. Watson and S.
- cancer e.g. G.D. Demetri et al., Proc. Natl. Acad. Sci. USA 3951-3956, 96 (1999)
- multiple sclerosis e.g. M. Niino et al., Neuroimmunology 40-48, 116 (2001)
- thiazolidinediones can modulate the functions of white blood blood cells (e.g. R. Garg et al, Hypertension 430-435, 36 (2000); N. Marx et al, Circ. Res. 703-710, 90 (2002)) as well as reduce their number in the circulation (S.M. Haffner et al, Circulation 679- 684, 106 (2002)).
- European Patent 306228 describes a class of PPAR gamma agonists which are thiazolidinedione derivatives for use as insulin sensitisers in the treatment of Type II diabetes mellitus. These compounds have anti-hyperglycaemic activity.
- US patent 6,294,580 describes a series of PPAR gamma agonist compounds not of the thiazolidinedione class but which are instead O- and N- substituted derivatives of tyrosine which nevertheless are effective as insulin sensitisers in the treatment of Type II diabetes mellitus.
- N-(2- benzoylphenyl)-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-L-tyrosine also known as 2(S)-(2-Benzoyl-phenyIamino)-3- ⁇ 4-[2-5- methyl- 2-phenyl-oxazol-4-yl)-ethoxy]- phenyl ⁇ -propionic acid, or by the generic name farglitazar).
- US Patent 5,594,015 (Kurtz et al) describes the use of certain thiazolidinedione derivatives including pioglitazone and ciglitazone for the treatment of psoriasis through a mechanism involving inhibition of proliferation of keratinocytes.
- This patent describes a range of presentations by which the drug substance may be administered to the patient, including,: for example, by applying a cream or oil of around 1-2% strength directly to the psoriatic lesion, or by administering the medication orally.
- US Patent 6,403,656 (Rivier et al) reports similar findings to those of Kurtz, together with the observation that the level of expression of PPAR gamma in psoriatic lesions is reduced relative to the healthy state.
- This patent describes the use of PPAR gamma agonists including thiazolidinediones as well as certain tyrosine derivatives in the treatment of abnormalities of differentiation in epidermal cells, more particularly in the treatment of psoriasis, atopic dermatitis and eczema, acne, light induced keratosis and skin cancers.
- the compounds are indicated for oral, topical and parenteral administration, for example by the topical route in the form of pasty ointments, creams, milks, creamy ointments, powders, impregnated pads, solutions, gels, sprays, lotions or suspensions typically at a concentration of 0.001-10% preferably 0.01-1% by weight based on weight of composition.
- Neither Kurtz nor Rivier discuss how to achieve an anti-psoriatic effect without at the same time causing an unwanted anti- hyperglycaemic effect.
- Topical delivery of drugs provides a key advantage over systemic drug delivery as, ideally, the pharmacological effects of the drug administered will occur only locally and not systemically as plasma concentration will be too low to allow the drug to induce any pharmacological effect. This therefore offers the potential advantage of providing a larger therapeutic window with topical therapy than with systemic therapy.
- Prior art in the topical drug development field does not however describe ways to quantify this therapeutic window.
- the quantification of the therapeutic window is classically achieved by using animal models and by identifying effective and toxic plasma levels in the animal. These data are then used to design a dose to be administered to human to generate effective but safe plasma levels.
- the direct determination of the local concentration of a drug applied topically is difficult for two main reasons.
- the first reason is due to local contamination of the sampled tissue as the surface and the superior layers of the skin contain an amount of drug several order of magnitude superior to the lower skin layers like the viable epidermis or dermis. The amount recovered in the sampled tissue is therefore likely to be overestimated by a factor unknown.
- the second reason concerns the determination within such a sample of the level of bound and unbound drug.
- drugs Due to the absence of a manner of intelligently pre-selecting the desired dosage, and the need to be cautious in the performance of clinical trials which results in a tendency to under-dose, many drugs fail to achieve their therapeutic potential.
- Some drugs such as PPAR gamma agonists, are capable of exhibiting a number of different therapeutic effects some of which will be desired and some of which will not be desired in a given clinical situation. For example one therapeutic effect may arise when the drug is administered topically and another when administered systemically. Thus there is needed a method of achieving the desired therapeutic effect without the undesired one.
- compositions According to the classical way of describing pharmaceutical compositions, whether they be oral or topical preparations, it is primarily the amount of drug present in these pharmaceutical compositions which is used to characterise the composition.
- the amount in the dose given is usually a good indicator of the dose absorbed and therefore of the plasma concentration.
- Variation in plasma levels achieved after the dosing of the same drug in two different oral preparations is usually small.
- the amount of drug present in the preparation is classically used to describe the preparation, as for oral preparations, and is usually expressed as the percentage of drug in the preparation.
- the variability in the amount absorbed is large compared to oral dosage forms as the bioavailability of topical drugs is generally low. This variability can be of one or two orders of magnitude depending on the excipients used in the preparation.
- Example 1 which describes two different topical formulations of rosiglitazone, shows that a topical Gel B containing 100 fold less rosiglitazone, nevertheless delivered more of this compound than the Gel A. This goes to show that the use of the dose applied can therefore be a very poor way of describing a topical preparation.
- the window is bounded at the upper end by a flux that is sufficiently low that it does not result in any undesired systemic pharmacological effect and is bounded at the lower end by a flux that is sufficiently high that it leads to a desired local pharmacological effect.
- the prior art describes use of mathematical models to predict local concentration in epidermis or dermis (Kubota et al. (1993) J. Pharm. Sci. 82, 450-456 ;
- the stratum corneum (SC) or horny layer is the outermost layer of the skin and the main barrier to percutaneous absorption of chemical compounds despite being a very thin layer of an average thickness of 10-20 ⁇ m.
- the barrier properties of the SC are attributed to the highly organised layers of flattened, polygonal corneocytes and specialised intercellular lipids.
- the corneocytes are cell remnants of the terminally differentiated keratinocytes found in the basal layer of the epidermis at the epidermal- dermal junction.
- the corneocytes are surrounded by a practically insoluble and very resistant cell envelope.
- the intercellular space is filled with lipids organised in stacked bilamellar structures sandwich with a continuous water phase.
- the lipids located in the intercellular space play a key role in the barrier formation.
- the viable epidermis constitutes a dynamic system in which the keratinocytes, proliferated from the basal layer, differentiate as they progress towards the SC and get transformed into corneocytes.
- the turnover time for a keratinocyte from the basal layer to the skin surface is about 28 days for normal skin. It also contains specialised cells like melanocytes, which protect the body against UV radiation.
- the viable epidermis does not contain blood vessels as it receives nourishment from the dermis by passive diffusion.
- the viable epidermis is not considered as having strong barrier properties.
- the Dermis The dermis is situated below the viable epidermis. It is approximately 1 to 3 mm thick and makes the bulk of the skin. It consists of a matrix of connective tissue made from fibrous proteins like elastin and collagen.
- the main functions of the dermis are to give mechanical strength and elasticity to the skin barrier, to supply oxygen and nutrients, and to remove waste products.
- the dermis has an extensive vascular supply, which regulates temperature and pressure, delivers nutrients, removes waste products and mobilises defence forces.
- Terminal hair follicles e.g. hair on the head
- a large hair is associated with a large sebaceous gland.
- the root of this hair may extend more than 3mm below the skin surface into the subcutaneous fatty tissue.
- Vellus hair follicles e.g. fine hairs on the face in women
- Vellus hair follicles in which only a small sebaceous gland is associated with a fine hair. Its roots extend less than 1 mm in the dermis.
- Sebaceous follicles (or sebaceous gland follicles), characteristics of human beings and not present in animals. They are found mainly on the face and the central parts of chest and back. It consists of 4 parts: the sebaceous gland lobes that secretes sebum (a mixture of lipids), the sebaceous ducts that connects the lobes and the secretory duct, a small vellus hair and the secretory duct which is a long duct lined by keratinocytes that is the large conducting duct that conducts the sebum coming from the sebaceous gland to the skin surface. The keratinocytes produce corneocytes which normally are ejected outwards. The sebaceous duct is situated approximately 0.5 mm below the skin surface.
- the sweat glands are found mainly on the face and the central parts of chest and back. It consists of 4 parts: the sebaceous gland lobes that secretes sebum (a mixture of
- Sweat glands are tubular glands distributed almost over the entire human body. Each gland has a secretory part located below the dermis in the subcutaneous ⁇ tissue and an excretory duct that ultimately opens directly on the skin surface. These glands produce perspiration.
- a number of skin conditions may desirably be treated by topical administration of an active drug substance.
- an active drug substance for example:
- Psoriasis is an inflammatory skin condition which has been described in J Invest Dermatol (1983) 81 503-506 and J Amer Acad Dermatol (1983) 8(5) 645-647.
- the psoriatic skin lesions are inflammatory, red, sharply delimited plaques of various shapes with characteristics silvery lustrous scaling.
- the second one occurs in the dermis where there is a strong inflammatory reaction coupled with a network of capillaries expanding from the one present in normal skin (this is called angiogenesis)
- angiogenesis a network of capillaries expanding from the one present in normal skin
- the target layer of the skin is usually both the bottom of the epidermis and the top of the dermis.
- both the bottom of the epidermis and the top of the dermis are considered the target sites for the drug's effect, as such drugs can affect (a) the differentiation/proliferation of keratinocytes process (bottom of epidermis), (b) the inflammatory process (top of dermis), and (c) the angiogenesis process (top of dermis).
- Atopic dermatitis is an inflammatory skin condition which has been described in J Invest Dermatol (1982) 79 243-245, Br J Dermatol (1988) 118, 517-522, J Am Acad Dermatol (1995) 33, 969-972 and J Dermatol Sci (2000) 23, 178-182 - "Atopic Dermatitis: From Pathogenesis to treatment" - author/editor Leung D-Y.M. - 1996 - Springer-Veriag .
- Atopic dermatitis is the most common form of dermatitis and is a chronic inflammatory skin condition whose classic feature is itchy skin. The great majority of cases occur in infancy and childhood.
- the skin is dry, flaky, rough, and can be secondarily infected and show oozing and crusts.
- the skin barrier property of atopic dermatitis lesions is viewed as being down compared to normal.
- the main treatment skin tissue target for this disease is the top layer of the dermis where the inflammation occurs.
- the top of the dermis is considered the target for the drug's effect, as such drugs can affect the inflammatory process (top of dermis).
- Facial acne is one of the most common diseases in dermatology. It occurs at puberty in almost every one, although to different extents and regress in early adulthood.
- the preferred sites are naturally on the face as this is a disease affecting the sebaceous follicles. It is characterised by seborrhoea, disturbed keratinisation in the follicles with comedones and subsequent inflammatory papules, pustules, and nodular abscesses and scars.
- seborrhoea disturbed keratinisation in the follicles with comedones and subsequent inflammatory papules, pustules, and nodular abscesses and scars.
- One of the most important factors in acne is the superior production of sebum in acne sites as opposed to healthy skin sites. Sebaceous follicles are densely populated by bacteria and fungi. In the deeper anaerobic area of the sebaceous glands one finds propionibacteria. These produce lipases and are regarded as a substantial factors in the pathogenesis of acne.
- the first detectable sign of acne is increased production of corneocytes in the secretory duct, but these are no longer extruded outwards. Comedones (blockage of the sebaceous follicle) occur therefore through hyperkeratosis associated with proliferation and retention. Bacteria proliferation and inflammation can then occur [Braun-Falco O., Plewig G., Wolff H.H. & Winkelmann R.K.
- the whole dermis is considered the target for the drug's effect, as such drugs can affect (a) the differentiation/proliferation of keratinocyte that cover the wall of the sebaceous ducts, which ducts run down into the dermis (whole dermis), (b) the inflammatory process that occurs around the sebaceous gland (whole dermis), and (c) the excess sebum production (on the external surface of sebocyte gland) (whole dermis).
- Rosacea is a condition having as a classic symptoms a persistent flushing of the face, leading to a polymorphic picture of persistent redness, papules, telangiectasia, thickening and coarsening of the skin and in its most extreme form gross enlargement and deformity of the nose.
- the areas most characteristically affected are the central convex areas of the face (nose, forehead, cheeks and chin), although the scalp, upper chest, back and even the limbs may be involved.
- the onset of rosacea is preceded by episodic flushing unaccompanied by sweating, these attacks being readily triggered by local stimuli including hot drinks, spicy food, alcohol, excessive sunlight and emotion.
- Erythema which is accompanied by a burning sensation, gradually becomes more persistent and is associated with increasingly prominent telangiectasia. More advanced stages show follicular and non-follicular papules and pustules without comedones followed by persistent tissue thickening due to oedema leading ultimately to a punished d'orange appearance and rhinophyma. Untreated, rosacea becomes slowly but inexorably more severe, although there may be temporary remissions and severe relapses on the way depending on the exposure to or withdrawal of exacerbating factors.
- the top of the dermis is considered as a target site for the drug's effect, as such drugs can affect (a) the inflammatory process (top of dermis), and (b) the angiogenesis process (top of dermis).
- Skin Photoageing is the gradual deterioration of cutaneous structure and function following long term, recurrent exposure to sunlight or artificial UVR sources. It apparently occurs as a result of cumulative DNA damage resulting from recurrent, acute DNA injury and from the effects of chronic inflammation. Epidermis and dermis are both affected by UVB and the dermis is significantly affected by UVA as well. Histologically, there is a mild inflammatory infiltrate and profuse upper dermal accumulation of a form of amorphous, degenerate elastic tissue, known as elastosis. Both are probably responses to UVR-induced elastin promoter, metalloproteinase and cytokine activation.
- the dermis is the main skin target site for drug therapy.
- the whole dermis is considered as the target site for the drug's effect, as such drugs can affect (a) the differentiation/proliferation of the poorly differentiated cells of the dermis (whole dermis), (b) the inflammatory process (top of dermis), (c) the production of collagen break down product (whole dermis) and (d) the Retinoid X Receptors (whole dermis).
- Skin cancer can be present in many forms that can affect all the viable skin tissues (epidermis, dermis or appendages). The different forms can be benigm or malignant tumours. Their diversity is described in the 3 chapters of Textbook in
- the target site is therefore the whole depth of the skin viable tissue, ranging from the epidermis to the bottom of the dermis.
- the bottom of the epidermis as well as the whole dermis are considered as the target site for the drug's effect, as such drugs can affect (a) the differentiation/proliferation of skin cells [melanocytes in particular] (bottom of epidermis and whole dermis) and (b) the angiogenesis process (top of dermis).
- a method for treating a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands and skin cancer which comprises administering topically to the skin of a patient in need of treatment a pharmaceutical composition containing a drug substance which is a PPAR gamma agonist characterised in that the formulation delivers to the skin a nominal flux of said drug substance which is greater than the minimum nominal flux required to cause a therapeutic effect against the skin condition (hereinafter “lower limit nominal flux”) and less than the minimum nominal flux which will cause a systemic anti-hyperglycaemic effect (hereinafter “upper limit nominal flux”).
- the minimum nominal flux which will cause a systemic anti-hyperglycaemic effect (“upper limit nominal flux”) is defined in this invention as the flux which results in a peak plasma concentration which is comparable with (for example the same as or within around 20%, ideally the same as) that obtained by administering the PPAR gamma agonist with a therapeutic dose by the oral route ("oral therapeutic dose").
- An oral therapeutic dose is defined as a dose that would lead to a substantial systemic anti-hyperglycaemic effect if dosed to a patient suffering from Type II diabetes mellitus or another condition alleviated by insulin sensitivity enhancement.
- the method is not limited to the treatment of patients suffering from such conditions.
- a pharmaceutical composition containing a drug substance which is a PPAR gamma agonist in the topical treatment to the skin of a patient suffering from a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands, and skin cancer characterised in that the composition delivers to the skin a nominal flux of said drug substance which is greater than the minimum nominal flux required to cause a therapeutic effect against the skin condition and less than the minimum nominal flux which will cause a systemic anti-hyperglycaemic effect.
- compositions containing a drug substance which is a PPAR gamma agonist in the manufacture of a medicament for the topical treatment to the skin of a patient suffering from a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands, and skin cancer characterised in that the composition delivers to the skin a nominal flux of said drug substance which is greater than the minimum nominal flux required to cause a therapeutic effect against the skin condition and less than the minimum nominal flux which will cause a systemic anti-hyperglycaemic effect.
- the lower limit nominal flux and the upper limit nominal flux are respectively given (expressed in units of ng/cm 2 /hr) by equations (1) and (2) as follows: (a) in the case of psoriasis equation (1 ) is:
- Z C * / [20 * (100-PBF)] wherein: Z is expressed in units of ng/ml and is the target local free (i.e. unbound) concentration that is expected to have a therapeutic effect against the skin condition.
- Z should correspond to the peak plasma free drug concentration generated by dosing these drugs orally to treat effectively Type II diabetes mellitus.
- the appropriate value of Z may be determined experimentally in vivo by conventional known means using standard protocols.
- C is expressed in units of ml/hr and is the rate of clearance of the drug substance. Clearance may be determined experimentally in vivo by conventional known means using standard tests. For example it can be determined from the plasma concentration in response to a defined input of drug using the equation given below:
- Plasma bound fraction is the plasma bound fraction.
- Plasma bound fraction may be determined experimentally in vitro by conventional known means using standard tests (preferably a method employing equilibrium dialysis).
- nominal flux is meant the flux that passes through healthy skin in a healthy individual (i.e. not diseased skin) on a body site such as the trunk, abdomen, legs, back, arms (but not the face), especially the back, averaged over a 24 hour period.
- the equations take account of the different barrier and clearance properties of skin in disease conditions and on the face (for example the skin of the face is approximately 5 times more permeable than the skin of other parts of the body).
- the nominal flux of a given composition may be determined by an in vivo measurement or may be estimated using an in vitro measurement using the tests given below.
- the nominal flux is a flux averaged over a 24 hr period it follows that the flux may be achieved through use of any suitable dose regimen (for example application a number of times per day, eg twice per day, or application every other day). It is expected that the same formulation will be applied on each treatment, although this is not required and, for example, one formulation could be applied at one time in the day and another formulation at another time in the day. In the event that the calculated figure for Equation (2) is less than that for Equation (1) then the drug substance in question is not suitable for use in the method.
- the lower limit nominal flux is 10/3 times greater than the minimum nominal flux required to cause a therapeutic effect against the skin condition.
- the upper limit nominal flux is one-fifth of the maximum nominal flux which will cause a systemic anti-hyperglycaemic effect.
- the lower limit nominal flux is 10/3 times than that given above in equations (1).
- the upper limit nominal flux is one fifth of that given above in equations (2).
- the drug is rosiglitazone.
- rosiglitazone may be employed as a pharmaceutical acceptable salt eg the maleate, however weights given herein are calculated based on rosiglitazone base.
- the value Z for rosiglitazone is 1.7 ng/ml
- Peak plasma concentration for a 8mg dose is about 600 ng/ml (P.J. Cox et al, 'Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidine dione insulin sensitizer, in humans', Drug Metabolism and Disposition, 2000, 28, p772-780); 1.7 is 600 * (100-99.72)/100J.
- the clearance of rosiglitazone is 2780 ml/hr (in adults) [P.J. Cox et al, 'Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidine dione insulin sensitizer, in humans', Drug Metabolism and Disposition (2000) 28, 772-780]
- the plasma bound fraction of rosiglitazone is 99.72% [P.J. Cox et al, 'Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidine dione insulin sensitizer, in humans', Drug Metabolism and Disposition (2000) 28, 772-780]
- the oral therapeutic dose for rosiglitazone is 4mg in a single dose or two divided doses per day.
- a method for treating a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands and skin cancer which comprises administering topically to the skin of a patient in need of treatment a pharmaceutical composition containing rosiglitazone or a salt thereof characterised in that the formulation delivers a nominal flux of rosiglitazone to the skin which is greater than A and less than B where A and B are as follows:
- a method for treating a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands and skin cancer which comprises administering topically to the skin of a patient in need of treatment a pharmaceutical composition containing rosiglitazone or a salt thereof characterised in that the formulation delivers a nominal flux of rosiglitazone to the skin which is greater than A and less than B where A and B are as follows:
- the drug is pioglitazone.
- pioglitazone may be employed as a pharmaceutical acceptable salt (such as the hydrochloride), however weights given herein are calculated based on pioglitazone base.
- the value Z for pioglitazone is 3.5 ng/ml
- Peak plasma concentration for a 30mg dose is about 700 ng/ml
- ['Clinical pharmacokinetics of pioglitazone' - D.A. Eckland and M. Danhof - 2000- 108-Suppl.2-S234-S242- Exp. Clin. Endocrinol. Diabetes; 3.5 is 700*(100-99.5V100]
- the plasma bound fraction of pioglitazone is 99.5% [Plasma protein binding >99% (Product Information ACTOS, 1999)]
- the oral therapeutic dose of pioglitazone is 15mg in a single dose or two divided doses per day.
- a method for treating a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands and skin cancer which comprises administering topically to the skin of a patient in need of treatment a pharmaceutical composition containing a pioglitazone or a salt thereof characterised in that the formulation delivers a nominal flux of pioglitazone to the skin which is greater than A and less than B where A and B are as follows: (a) in the case of psoriasis A is 1.5 (preferably 5.8) and B is 84;
- a method for treating a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, 10 photoageing of the face, photoageing of the hands and skin cancer which comprises administering topically to the skin of a patient in need of treatment a pharmaceutical composition containing a pioglitazone or a salt thereof characterised in that the formulation delivers a nominal flux of pioglitazone to the skin which is greater than A and less than B where A and B are as follows: 15 (a) in the case of psoriasis A is 4.8 and B is 17;
- the drug is troglitazone. It will be understood that troglitazone may be employed as a pharmaceutical acceptable salt however weights given herein are calculated based on troglitazone base.
- the value Z for troglitazone is 7.5 ng/ml [Peak plasma concentration for a 400mg dose is about 1500 ng/ml ['Lack of effect of Type II diabetes on the
- the plasma bound fraction of troglitazone is 99.5% [Plasma protein binding >99% (Product Information REZULIN, 1999)] .
- the oral therapeutic dose of troglitazone is 200mg in a single dose or two divided doses per day.
- a method for treating a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands and skin cancer which comprises administering topically to the skin of a patient in need of treatment a pharmaceutical composition containing troglitazone or a salt thereof characterised in that the formulation delivers a nominal flux of troglitazone to the skin which is greater than A and less than B where A and B are as follows:
- a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands and skin cancer
- a pharmaceutical composition containing troglitazone or a salt thereof characterised in that the formulation delivers a nominal flux of troglitazone to the skin which is greater than A and less than B where A and B are as follows:
- a further embodiment of the invention consists in varying the dose regimen of a PPAR gamma agonist delivered to the skin.
- PPAR gamma agonists deliver their full pharmacological potential over a relatively long treatment period that normally ranges from 4 to 18 weeks (J.J. Nolan et al, 'Rosiglitazone taken once daily provides effective glycaemic control in patients with Type II diabetes mellitus', Diabetic Medicine (2000) 17, 287-294 ; P.Raskin et al, 'Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes', Diabetologia (2000) 43, 278-284 ; L.S.
- Phillips et al,'Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with Type II diabetes', Diabetes Care (2001) 24(2), 308- 315 ; P. Raskin et al., 'A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated Type II diabetes', Diabetes Care (2001) 24(7), 1226-1232).
- the pharmacological benefit delivered is dose dependant.
- the rate at which this pharmacological benefit is delivered is also dose dependant.
- PPAR gamma agonists can be administered in the following ways.
- the treatment can be divided into two parts.
- the first part of the treatment consists of delivering a high topical dose for a short time ranging from one day to 12 weeks, preferably ranging from one day to 2 weeks.
- the second part of the treatment consists of delivering a lower dose, either topically or orally for the remaining part of the treatment. If for the second part of the treatment, the drug is delivered orally, it is preferred not to exceed the established orally safe dosage regimen
- a method for treating a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands and skin cancer which comprises administering topically to the skin of a patient in need of treatment a first pharmaceutical composition for a first period of time and a second pharmaceutical composition for a second period of time, each pharmaceutical formulation containing a drug substance which is a PPAR gamma agonist characterised in that the first formulation delivers to the skin a nominal flux of said drug substance which is greater than the minimum nominal flux required to cause a therapeutic effect against the skin condition (hereinafter "lower limit nominal flux”) and less than the minimum nominal flux which will cause a system
- compositions containing a drug substance which is a PPAR gamma agonist in the topical treatment to the skin of a patient suffering from a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands, and skin cancer characterised in that a first composition used for a first period of time delivers to the skin a nominal flux of said drug substance which is greater than the minimum nominal flux required to cause a therapeutic effect against the skin condition (hereinafter "lower limit nominal flux”) and less than the minimum nominal flux which will cause a systemic anti-hyperglycaemic effect and a second composition used for a second period of time delivers a nominal flux of said drug substance to the skin which is greater than the lower limit nominal flux but is less than the nominal flux delivered for the first period of time.
- a first composition used for a first period of time delivers to the skin a nominal flux of said drug substance which is greater than the minimum nominal flux required to
- compositions containing a drug substance which is a PPAR gamma agonist in the manufacture of a medicament for the topical treatment to the skin of a patient suffering from a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands, and skin cancer characterised in that a first composition used for a first period of time delivers to the skin a nominal flux of said drug substance which is greater than the minimum nominal flux required to cause a therapeutic effect against the skin condition (hereinafter "lower limit nominal flux") and less than the minimum nominal flux which will cause a systemic anti- hyperglycaemic effect and a second composition used for a second period of time delivers a nominal flux of said drug substance to the skin which is greater than the lower limit nominal flux but is less than the nominal flux delivered for the first period of time.
- the values of the "lower limit nominal flux" and the "upper limit nominal flux” may be determined using the
- a method for treating a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands and skin cancer which comprises administering topically to the skin of a patient in need of treatment a first pharmaceutical composition for a first period of time and a second pharmaceutical composition for a second period of time, each pharmaceutical formulation containing a drug substance selected from rosiglitazone, pioglitazone and troglitazone, or a salt of any one thereof, characterised in that the first formulation delivers a nominal flux of said drug substance to the skin which is greater than A and less than B, wherein A and B are as defined above, and the second formulation delivers a nominal flux
- the first composition has a higher flux than the second composition in order to accelerate onset of therapeutic activity.
- the second composition of lower flux is intended to be suitable for maintenance therapy.
- the first period of time is a period of time long enough to establish onset of therapeutic activity, more particularly is long enough to establish at least 75% of maintenance level therapeutic activity.
- the first period of time will be between 1 day and 12 weeks, preferably 1 day to 2 weeks.
- the second period of time is the remainder of the treatment period.
- the second formulation delivers a nominal flux of drug substance to the skin which is greater than A as defined above but is less than the half the nominal flux delivered for the first period of time, more preferably less than one quarter nominal flux delivered for the first period of time.
- a method for treating a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands and skin cancer which comprises administering topically to the skin of a patient in need of treatment for a first period of time a pharmaceutical composition containing a drug substance which is a PPAR gamma agonist characterised in that the formulation delivers to the skin a nominal flux of said drug substance which is greater than the minimum nominal flux required to cause a therapeutic effect against the skin condition (hereinafter “lower limit nominal flux”) and less than the minimum nominal flux which will cause a systemic anti-hyperglycaemic effect (hereinafter "upper limit nominal flux”) and
- compositions containing a drug substance which is a PPAR gamma agonist in the topical treatment to the skin of a patient suffering from a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands, and skin cancer characterised in that the composition delivers to the skin for a first period of time a nominal flux of said drug substance which is greater than the minimum nominal flux required to cause a therapeutic effect against the skin condition and less than the minimum nominal flux which will cause a systemic anti- hyperglycaemic effect and said treatment is followed by administering said drug substance in an oral dosage form.
- a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands, and skin cancer characterised in that the composition delivers to the skin for a first period of time a nominal flux of said drug substance which is greater than
- a pharmaceutical composition containing a drug substance which is a PPAR gamma agonist in the manufacture of a medicament for the topical treatment to the skin of a patient suffering from a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands, and skin cancer characterised in that the composition delivers to the skin for a first period of time a nominal flux of said drug substance which is greater than the minimum nominal flux required to cause a therapeutic effect against the skin condition and less than the minimum nominal flux which will cause a systemic anti-hyperglycaemic effect and said treatment is followed by administering said drug substance in an oral dosage form.
- a skin condition selected from the list consisting of psoriasis, atopic dermatitis, facial acne, rosacea, photoageing of the face, photoageing of the hands, and skin cancer characterised in that the composition delivers to the skin for a first period of time a
- the topical composition has a relatively high flux in order to accelerate onset of therapeutic activity.
- the oral dosage form is intended to be suitable for maintenance therapy.
- the first period of time is a period of time long enough to establish onset of therapeutic activity, more particularly is long enough to establish at least 75% of maintenance level therapeutic activity.
- the first period of time will be between 1 day and 12 weeks, preferably 1 day to 2 weeks.
- the second period of time is the remainder of the treatment period.
- the oral dosage composition may be effective in causing a systemic anti-hyperglycaemic effect in patients sensitive to systemic PPAR gamma agonist therapy (eg patients suffering from Type II diabetes mellitus or who would otherwise benefit from insulin sensitivity enhancement).
- the PPAR gamma agonist is rosiglitazone
- the oral dosage form of rosiglitazone delivers 2 to 8mg per day.
- the oral dosage form of pioglitazone delivers 7.5 to 30mg per day.
- the oral dosage form of troglitazone delivers 10Omg to 400mg per day.
- formulations adapted for topical administration to the skin capable of delivering fluxes according to the methods described above.
- Suitable formulations include ointments and solidified water/oil emulsion variants thereof, pastes, water/oil creams or lotions, oil/water creams or lotions, gels and rigid foams.
- Ointments are hydrocarbon-based semisolid formulations containing dissolved 15 or suspended drugs. They can, for example be prepared by incorporating high melting waxes into mineral oil (liquid petrolatum). Due to problems of drug solubility, and inconvenience associated with their greasy nature, it is often more convenient to incorporate an aqueous medium into the hydrophobic base to yield an emulsion. Examples of such aqueous mediums are the use of propylene glycol or 20 Polyoxyethylene polymers (polyetheylene glycol). Pastes are ointments into which a high percentage of insoluble particulate solids have been incorporated.
- Creams and lotions are semi-solid emulsion systems and the term is applied both to water/oil or oil/water.
- the oil phase of an emulsion may comprise from 5-95% preferably from 5 to 25 40% of the composition by weight.
- Gel formulations are semi-solid systems in which a liquid phase is trapped in a polymeric matrix of a natural or synthetic gum.
- Rigid foams are systems in which air or some other gas is emulsified in a liquid phase to the point of stiffening.
- composition contains an oily phase
- excipients of this phase may comprise an oil based on animal, vegetable, mineral, silicone, fluorinated and/or synthetic oil.
- hydrocarbon oils such as; isohexadecane, paraffin oil or liquid petroleum jelly, petrolatum, microcrystalline wax, beeswax; perhydrosqualene, arara oil, sweet almond, calophyllum, palm, castor, avocado, jojoba, olive or cereal germ oil; alcohols such as oleyl alcohol, linoleyl or linolenyl alcohol, isostearyl alcohol, lanolin alcohol or octyl dodecanol.
- hydrocarbon oils such as; isohexadecane, paraffin oil or liquid petroleum jelly, petrolatum, microcrystalline wax, beeswax; perhydrosqualene, arara oil, sweet almond, calophyllum, palm, castor, avocado, jojoba, olive or cereal germ oil; alcohols such as oleyl alcohol, linoleyl or linolenyl alcohol, isostearyl alcohol, lanolin alcohol or octyl
- silicone oils such as dimethicones, dimethiconols, cyclomethicones, silicone waxes like alkyl dimethicones or stearoxytrimethylsilane, cross-linked silicone elastomers as well as other polydimethylsiloxanes derivatives, optionally phenylated, such as phenyltrimethicones.
- esters such as methyl myristate, ethyl myristate, isopropyl myristate, butyl myristate, isobutyl myristate, methyl palmitate, ethyl palmitate, isopropyl palmitate, octyl palmitate, 2-ethylhexyl palmitate, cetyl palmitate, C12-15 alkyl benzoate, ethyl oleate, decyl oleate, butyl stearate, isopropyl isostearate, dioctyl adipate, diisopropyl adipate, 2-ethylhexyl hexanoate, 2-ethylhexyl 2-ethylhexanoate, ethyl laurate, isohex
- An emulsification agent for dispersing the oil phase for example an anionic surfactant like carboxylic acids, carboxylic acids esters, sulfuric acid esters, sulfonic acids, amino acid amides; a cationic surfactant like polyoxyethylene alkyl amines', tetraalkyl ammonium salts; an amphoteric surfactant like phospholipids, N-alkyl amino acids, alkylamido alkylamines; a nonionic surfactants like fatty alcohols, alkoxylated fatty alcohols, polyoxyethylene-phenol esters, alkoxylated fatty acids, acyl sorbitans, polyoxyethylene-derivatives, acyl glycerides, polyoxyethylene alkyl amides, polyoxyethylene/polyoxypropylene block copolymers, polyoxyethylene silicone derivatives, alkylmethyl siloxane copolyol, alkyl-substituted polyvinyl polymers.
- emulsifying systems well known to the art and comprising of glyceryl stearate, glyceryl distearate, glyceryl oleate, propylene glycol stearate, glycol sterate, glyceryl stearate/PEG 100 stearate, sorbitan sesquioleate, cetyl alcohol, stearyl alcohol, sodium lauryl sulfate and cetomacrogol.
- An agent affecting the suspension of the oil phase for example a copolymer of C.sub.10 -C.sub.30 alkyl acrylates and acrylic or methacrylic acid or ester thereof; or an acrylamide/methylpropane-sulfonic acid copolymer.
- An agent for modifying its viscosity, and to provide textures which are gelled to a greater or lesser degree such as: cellulose derivatives (carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose); natural gums such as xanthan, guar and carob gums, scleroglucans, chitin or chitosan 5 derivatives, carrageenans; polycarboxyvinyl derivatives of the Carbomer type.
- compositions according to the invention may also comprise conventional additives and adjuvants for dermatological applications, such as preservatives, especially paraben esters like methylparaben, ethylparaben, propylparaben, butylparaben, or quaternary ammonium compounds like benzalkonium chloride, or
- moisturizers especially glycerin, butylene glycol, hexylene glycol, urea, hyaluronic acid or derivatives thereof; anti-free radical agents such as vitamin E or derivatives thereof; penetration enhancers especially propylene glycol; ethanol; isopropanol; dimethylsulfoxide; N-methyl-2- pyrrolidone; fatty acids/alcohols such as oleic acid, oleyl alcohol; terpenes such as
- limonene, menthol, 1 -8 cineole 20 limonene, menthol, 1 -8 cineole; alkyl esters such as ethyl acetate, butyl acetate; ion pairing agents such as salicylic acid.
- Example formulation bases include:
- Polyethylene glycol 4000 (Carbowax 4000) 50% (w/w), polyethylene glycol 400
- Oil phase spermaceti 12.5% (w/w), white wax 12.0%, almond oil 55.58%
- Aqueous phase sodium borate 0.5% (w/w), purified water 19%
- Oil phase stearic acid 13% (w/w), stearyl alcohol 1 %, cetyl alcohol 1%
- Aqueous phase glycerine 10% (w/w), methylparaben 0.025%, propylparaben 0.015%, potassium hydroxide 0.9%, purified water qs to 100%
- Oil phase stearic alcohol 15% (w/w), beeswax 8%, sorbitan monooleate 1.25%
- Aqueous phase 70% sorbitol solution 7.5% (w/w), polysorbate 80 3.75%, methylparaben 0.025%, propylparaben 0.015%, purified water qs to 100%
- Methocel 90 HC 4000 0.8% (w/w), Carbopol 934 0.24%, propylene glycol 16.7%, methylparaben 0.015%, sodium hydroxide qs to pH 7, purified water qs to 100%
- drug substances for oral administration may, for example, be in solid oral dosage forms or liquid oral dosage forms.
- Example solid oral dosage forms include tablet or capsule form and may as necessary contain conventional excipients such as binding agents, fillers, lubricants, glidants, disintegrants and wetting agents. Unit dose compositions are preferred.
- binding agents include acacia, alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, dextrates, dextrin, dextrose, ethylcellulose, gelatin, liquid glucose, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium aluminium silicate, maltodextrin, methyl cellulose, polymethacrylates, polyvinylpyrrolidone, pregelatinised starch, sodium alginate, sorbitol, starch, syrup, tragacanth.
- fillers include calcium carbonate, calcium phosphate, calcium sulphate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, compressible sugar, confectioner's sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, dibasic calcium phosphate, fructose, glyceryl palmitostearate, glycine, hydrogenated vegetable oil-type 1 , kaolin, lactose, maize starch, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, microcrystalline cellulose, polymethacrylates, potassium chloride, powdered cellulose, pregelatinised starch, sodium chloride, sorbitol, starch, sucrose, sugar spheres, talc, tribasic calcium phosphate, xylitol.
- lubricants include calcium stearate, glyceryl monostearate, glyceryl palmitostearate, magnesium stearate, microcrystalline cellulose, sodium benzoate, sodium chloride, sodium lauryl sulphate, stearic acid, sodium stearyl fumarate, talc, zinc stearate.
- glidants include colloidal silicon dioxide, powdered cellulose, magnesium trisilicate, silicon dioxide, talc.
- disintegrants examples include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, croscarmellose sodium, crospovidone, guar gum, magnesium aluminium silicate, microcrystalline cellulose, methyl cellulose, polyvinylpyrrolidone, polacrilin potassium, pregelatinised starch, sodium alginate, sodium lauryl sulphate, sodium starch glycollate.
- An example of a pharmaceutically acceptable wetting agent is sodium lauryl sulphate.
- the solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art.
- the tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
- Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
- the nominal flux delivered by a given topical composition may be determined in vivo or in vitro. The in vivo method which employs healthy human volunteers is as follows
- the test composition is applied to the back of an individual at around 2 mg of formulation per cm 2 .
- the area of the site treated must be measured.
- the site treated must be left opened for 2 hours prior to the individual wearing a cotton T-shirt for the remainder of the study.
- Plasma concentration measurements are made every 4 hours over a 24 hours period.
- the flux is calculated from the plasma level achieved using classical pharmacokinetics as described by Hadgraft et al ('Investigations on the percutaneous absorption of the antidepressant rolipram in vitro and in vivo'-Hadgraft et al (1990) Pharm. Res. 7, 1307-1312).
- Equation A Equation A:
- Flux (ng/cm 2 /hr) Mean total plasma concentration over 24 hours (ng/ml) * total systemic clearance (ml/hr)/surface area (cm 2 )
- the alternative in vitro method involves an in vitro percutaneous study.
- the method which essentially follows Colipa recommendations (European Commission - 99/III/COS/87 - Basic Criteria for the in vitro assessment of percutaneous absorption of cosmetic ingredients - SCCNFP/0167/99/Final - 23rd June 1999) requires the. use of opened diffusion cells (flow-through type, eg Permegear brand) that are temperature controlled to 32 °C (to mimic skin temperature) and which allow application of a thin film with an upper donor chamber and a lower receptor chamber.
- the diffusion cells should be sufficiently large to allow application of a clinically relevant dose, preferably greater than 2 cm 2 in area.
- a clinically relevant dose is considered to be around 2mg of the formulation per cm2 for the skin condition treated.
- the human skin used should be dermatomed to approximately 300-500 ⁇ m and sourced from the back of the human. Skin batch integrity should be assessed with the use of a controlled solution of known flux (e.g. caffeine, methyl paraben).
- Drug follows through to a receptor mimicking well physiological condition and which does not contain solvents or other materials that would influence the integrity of the skin barrier.
- the preferred receptor is aqueous Phosphate Buffer Salined receptor.
- Study time is equal to about 24 hours, with periodic sample measurement and receptor replacement eg at 4 hour intervals.
- the flux is determined by the in vivo measurement, although that it would be expected that the in vitro system is a satisfactory model for the in vivo system.
- the skin condition of particular interest is psoriasis.
- compositions for use in the aforementioned methods and uses which comprise a PPAR gamma agonist and a physiologically acceptable carrier.
- the carrier will be physiologically acceptable on topical administration.
- a pharmaceutical composition comprising a ; drug substance which is a PPAR gamma agonist and a physiologically acceptable carrier characterised in that the formulation delivers to the skin a nominal flux of said drug substance which is greater than a lower limit nominal flux defined as the minimum nominal flux required to cause a therapeutic effect against the skin condition and less than an upper limit nominal flux defined as the minimum nominal flux which will cause a systemic anti-hyperglycaemic effect.
- the PPAR gamma agonist may be employed in combination with another therapeutic substance of .
- benefit in topical administration for example a corticosteroid (eg fluticasone propionate or mometasone furoate), a vitamin D3 derivative (eg calcipotriol), a retinoid (eg retinol,tazarotene, or trans- or cis-retinoic acid) or an immunomodulator (eg pimecrolimus or tacrolimus).
- a corticosteroid eg fluticasone propionate or mometasone furoate
- a vitamin D3 derivative eg calcipotriol
- a retinoid eg retinol,tazarotene, or trans- or cis-retinoic acid
- an immunomodulator eg pimecrolimus or tacrolimus
- treatment embraces treatment of established conditions as well as prophylaxis if appropriate.
- the drug substance of particular interest is rosiglitazone or a salt thereof, particularly rosiglitazone maleate.
- Pioglitazone (including salts thereof, such as the hydrochloride) is also of particular interest. Examples
- Gel A delivers a flux of rosiglitazone which is expected to be insufficient for atopic dermatitis. However the flux from Gel A would be expected to be sufficient for photoageing of the face.
- Gel B delivers a flux of rosiglitazone which is expected to be sufficient for atopic dermatitis (also photoageing of the face, facial acne and rosacea).
- Figure 1 The structure of mammalian skin.
- Figure 2 Profile of the percutaneous flux with time of formulations of Example 1.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04711167A EP1594959A4 (en) | 2003-02-17 | 2004-02-13 | Novel therapeutic method and compositions for topical administration |
JP2006503567A JP2006517973A (en) | 2003-02-17 | 2004-02-13 | Novel therapeutic method and composition for topical administration |
US10/545,773 US20060159648A1 (en) | 2003-02-17 | 2004-02-13 | Novel therapeutic method and compositions for topical administration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0303609.2A GB0303609D0 (en) | 2003-02-17 | 2003-02-17 | Novel therapeutic method and compositions |
GB0303609.2 | 2003-02-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004073622A2 true WO2004073622A2 (en) | 2004-09-02 |
WO2004073622A3 WO2004073622A3 (en) | 2005-01-20 |
Family
ID=9953158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/004329 WO2004073622A2 (en) | 2003-02-17 | 2004-02-13 | Novel therapeutic method and compositions for topical administration |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1594959A4 (en) |
JP (1) | JP2006517973A (en) |
GB (1) | GB0303609D0 (en) |
WO (1) | WO2004073622A2 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2894477A1 (en) * | 2005-12-13 | 2007-06-15 | Galderma Res & Dev | USE OF NAVEGLITAZAR FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DERMATOLOGICAL DISEASES |
WO2008104557A1 (en) * | 2007-02-28 | 2008-09-04 | Giuliani International Limited | Ppar-gamma agonists for the induction of cationic antimicrobial peptide expression as immunoprotective stimulants |
US8138357B2 (en) | 2005-07-22 | 2012-03-20 | Giuliani International Limited | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field |
US8153841B2 (en) | 2005-07-22 | 2012-04-10 | Giuliani International Limited | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field |
EP2515830A1 (en) * | 2009-12-21 | 2012-10-31 | Sarah Bacus | Compositions and methods for increasing cellular fat and bleaching skin |
US8501806B2 (en) | 2008-12-05 | 2013-08-06 | Nogra Pharma Limited | Methods for preventing or reducing colon carcinogenesis |
US8754127B2 (en) | 2009-02-16 | 2014-06-17 | Nogra Pharma Limited | Alkylamido compounds and uses thereof |
US8946256B2 (en) | 2009-12-21 | 2015-02-03 | Biocosmeceuticals, LLC | Compositions and methods for treatment of vitiligo |
WO2015109037A1 (en) * | 2014-01-15 | 2015-07-23 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
US9416117B2 (en) | 2013-03-14 | 2016-08-16 | Deuterx, Llc | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US9682050B2 (en) | 2012-04-18 | 2017-06-20 | Nogra Pharma Limited | Methods of treating lactose intolerance |
US9682923B2 (en) | 2012-02-09 | 2017-06-20 | Nogra Pharma Limited | Methods of treating fibrosis |
US9925175B2 (en) | 2007-09-26 | 2018-03-27 | Deuterx, Llc | Deuterium-enriched pioglitazone |
US10722503B2 (en) | 2017-02-22 | 2020-07-28 | Jeffrey L. SUGARMAN | Glitazones for topical application |
US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
US11905232B2 (en) | 2019-02-08 | 2024-02-20 | Nogra Pharma Limited | Process of making 3-(4′-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5594015A (en) * | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
WO2002076177A2 (en) * | 2001-03-23 | 2002-10-03 | Bethesda Pharmaceuticals, Inc. | Design and synthesis of optimized ligands for ppar |
US6831102B2 (en) * | 2001-12-07 | 2004-12-14 | Bristol-Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
WO2003094845A2 (en) * | 2002-05-08 | 2003-11-20 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
-
2003
- 2003-02-17 GB GBGB0303609.2A patent/GB0303609D0/en not_active Ceased
-
2004
- 2004-02-13 EP EP04711167A patent/EP1594959A4/en not_active Withdrawn
- 2004-02-13 JP JP2006503567A patent/JP2006517973A/en not_active Withdrawn
- 2004-02-13 WO PCT/US2004/004329 patent/WO2004073622A2/en active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of EP1594959A4 * |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8710100B2 (en) | 2005-07-22 | 2014-04-29 | Nogra Pharma Limited | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field |
US10016381B2 (en) | 2005-07-22 | 2018-07-10 | Nogra Pharma Limited | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field |
US9561202B2 (en) | 2005-07-22 | 2017-02-07 | Nogra Pharma Limited | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field |
US8138357B2 (en) | 2005-07-22 | 2012-03-20 | Giuliani International Limited | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field |
US9345680B2 (en) | 2005-07-22 | 2016-05-24 | Nogra Pharma Limited | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field |
US9133099B2 (en) | 2005-07-22 | 2015-09-15 | Nogra Pharma Limited | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field |
US8153841B2 (en) | 2005-07-22 | 2012-04-10 | Giuliani International Limited | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field |
WO2007068577A1 (en) * | 2005-12-13 | 2007-06-21 | Galderma Research & Development | Use of naveglitazar for preparing a pharmaceutical composition for use in the treatment of dermatological conditions |
FR2894477A1 (en) * | 2005-12-13 | 2007-06-15 | Galderma Res & Dev | USE OF NAVEGLITAZAR FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DERMATOLOGICAL DISEASES |
WO2008104557A1 (en) * | 2007-02-28 | 2008-09-04 | Giuliani International Limited | Ppar-gamma agonists for the induction of cationic antimicrobial peptide expression as immunoprotective stimulants |
AU2008220762B2 (en) * | 2007-02-28 | 2013-08-22 | Nogra Pharma Limited | PPAR-gamma agonists for the induction of cationic antimicrobial peptide expression as immunoprotective stimulants |
US11918567B2 (en) | 2007-09-26 | 2024-03-05 | Poxel Sa | Deuterium-enriched pioglitazone |
US10576071B2 (en) | 2007-09-26 | 2020-03-03 | Poxel Sa | Deuterium-enriched pioglitazone |
US9925175B2 (en) | 2007-09-26 | 2018-03-27 | Deuterx, Llc | Deuterium-enriched pioglitazone |
US10940143B2 (en) | 2007-09-26 | 2021-03-09 | Poxel Sa | Deuterium-enriched pioglitazone |
US8501806B2 (en) | 2008-12-05 | 2013-08-06 | Nogra Pharma Limited | Methods for preventing or reducing colon carcinogenesis |
US9913817B2 (en) | 2008-12-05 | 2018-03-13 | Nogra Pharma Limited | Methods for preventing or reducing colon carcinogenesis |
US8754127B2 (en) | 2009-02-16 | 2014-06-17 | Nogra Pharma Limited | Alkylamido compounds and uses thereof |
US10137101B2 (en) | 2009-02-16 | 2018-11-27 | Nogra Pharma Limited | Alkylamido compounds and uses thereof |
US10959970B2 (en) | 2009-02-16 | 2021-03-30 | Nogra Pharma Limited | Methods of treating hair related conditions |
US8796334B2 (en) | 2009-02-16 | 2014-08-05 | Nogra Pharma Limited | Methods of treating hair related conditions |
US10398667B2 (en) | 2009-02-16 | 2019-09-03 | Nogra Pharma Limited | Methods of treating hair related conditions |
US9901557B2 (en) | 2009-02-16 | 2018-02-27 | Nogra Pharma Limited | Methods of treating hair related conditions |
US9511041B2 (en) | 2009-02-16 | 2016-12-06 | Nogra Pharma Limited | Alkylamido compounds and uses thereof |
US8946256B2 (en) | 2009-12-21 | 2015-02-03 | Biocosmeceuticals, LLC | Compositions and methods for treatment of vitiligo |
EP2515830A1 (en) * | 2009-12-21 | 2012-10-31 | Sarah Bacus | Compositions and methods for increasing cellular fat and bleaching skin |
EP2515830A4 (en) * | 2009-12-21 | 2014-06-04 | B C Unlimited Liability Company | Compositions and methods for increasing cellular fat and bleaching skin |
US11753365B2 (en) | 2012-02-09 | 2023-09-12 | Nogra Pharma Limited | Methods of treating fibrosis |
US9682923B2 (en) | 2012-02-09 | 2017-06-20 | Nogra Pharma Limited | Methods of treating fibrosis |
US11046641B2 (en) | 2012-02-09 | 2021-06-29 | Nogra Pharma Limited | Methods of treating fibrosis |
US9682050B2 (en) | 2012-04-18 | 2017-06-20 | Nogra Pharma Limited | Methods of treating lactose intolerance |
US9416117B2 (en) | 2013-03-14 | 2016-08-16 | Deuterx, Llc | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US11918569B2 (en) | 2013-03-14 | 2024-03-05 | Poxel Sa | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US10265305B2 (en) | 2013-03-14 | 2019-04-23 | Poxel Sa | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US9833445B2 (en) | 2013-03-14 | 2017-12-05 | Deuterx, Llc | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US11123336B2 (en) | 2013-03-14 | 2021-09-21 | Poxel Sa | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
WO2015109037A1 (en) * | 2014-01-15 | 2015-07-23 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
US11141411B2 (en) | 2014-01-15 | 2021-10-12 | Poxel Sa | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
US10188639B2 (en) | 2014-01-15 | 2019-01-29 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
US10722503B2 (en) | 2017-02-22 | 2020-07-28 | Jeffrey L. SUGARMAN | Glitazones for topical application |
US11905232B2 (en) | 2019-02-08 | 2024-02-20 | Nogra Pharma Limited | Process of making 3-(4′-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof |
US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
Also Published As
Publication number | Publication date |
---|---|
EP1594959A2 (en) | 2005-11-16 |
EP1594959A4 (en) | 2006-05-03 |
WO2004073622A3 (en) | 2005-01-20 |
GB0303609D0 (en) | 2003-03-19 |
JP2006517973A (en) | 2006-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1594959A2 (en) | Novel therapeutic method and compositions for topical administration | |
Tanaji | Emulgel: A comprehensive review for topical delivery of hydrophobic drugs | |
KR101715631B1 (en) | Compositions and methods for skin care | |
JP5570992B2 (en) | Method and composition for treating skin diseases or skin lesions | |
DK1879595T3 (en) | Preparations and Methods for the Treatment of Hyperproliferative Epidermal Diseases | |
JP2023022177A (en) | Therapeutic topical compositions of apremilast | |
US9622950B2 (en) | Compositions for use in treatment of dermatological diseases and conditions | |
EP1635808A1 (en) | Topical use of valproic acid for the prevention or treatment of skin disorders | |
US20060159648A1 (en) | Novel therapeutic method and compositions for topical administration | |
US20110281947A1 (en) | Methods of administering diclofenac compositions for treating photodamaged skin | |
Foster et al. | Tazarotene. | |
JP5891651B2 (en) | Skin preparation for normalization of stratum corneum cell differentiation | |
RU2152785C1 (en) | Use of cgrp-antagonist for treatment of shingles and prurigos, composition and method of treatment | |
EP1594496A2 (en) | Novel therapeutic method and compositions for topical administration | |
US20130165526A1 (en) | Topical treatment with dapsone in g6pd-deficient patients | |
US20060142356A1 (en) | Novel therapeutic method and compositions for topical administration | |
WO2022175829A1 (en) | Topical formulations and compositions | |
JPH08109128A (en) | Preparation for treating allergic dermatopathy for external use | |
US10722503B2 (en) | Glitazones for topical application | |
US20230172960A1 (en) | Topical capecitabine for the treatment of hyperproliferative skin conditions | |
Chadha | Design, Optimization and Evaluation of a Novel Emulgel of Ibuprofen for Enhanced Skin Delivery using Formulating for Efficacy™ software | |
WO2017109761A1 (en) | Topical composition for the treatment of acne | |
WO2005060948A1 (en) | Use of fepradinol for the production of a pharmaceutical composition for the treatment of rosacea | |
MX2007006059A (en) | Composition for removal of skin pigmentation. | |
JP2008081468A (en) | Preventing or treating agent of psoriasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004711167 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006503567 Country of ref document: JP |
|
ENP | Entry into the national phase in: |
Ref document number: 2006159648 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10545773 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004711167 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10545773 Country of ref document: US |